Kaleido Biosciences (KLDO) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock KLDO vs. XTKG, SEGG, SOGP, MTC, MTBLY, STIX, STRM, AIXI, HCTI, and HKITShould you be buying Kaleido Biosciences stock or one of its competitors? The main competitors of Kaleido Biosciences include X3 (XTKG), Lottery.com (SEGG), LIZHI (SOGP), MMTec (MTC), Moatable (MTBLY), Semantix (STIX), Streamline Health Solutions (STRM), XIAO-I (AIXI), Healthcare Triangle (HCTI), and Hitek Global (HKIT). These companies are all part of the "computer software" industry. Kaleido Biosciences vs. Its Competitors X3 Lottery.com LIZHI MMTec Moatable Semantix Streamline Health Solutions XIAO-I Healthcare Triangle Hitek Global X3 (NASDAQ:XTKG) and Kaleido Biosciences (NASDAQ:KLDO) are both small-cap computer software companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, media sentiment, profitability and institutional ownership. Does the media refer more to XTKG or KLDO? In the previous week, X3's average media sentiment score of 0.00 equaled Kaleido Biosciences'average media sentiment score. Company Overall Sentiment X3 Neutral Kaleido Biosciences Neutral Do institutionals and insiders hold more shares of XTKG or KLDO? 1.9% of X3 shares are owned by institutional investors. Comparatively, 81.6% of Kaleido Biosciences shares are owned by institutional investors. 23.9% of X3 shares are owned by company insiders. Comparatively, 9.0% of Kaleido Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more volatility and risk, XTKG or KLDO? X3 has a beta of 1.48, meaning that its share price is 48% more volatile than the S&P 500. Comparatively, Kaleido Biosciences has a beta of -0.06, meaning that its share price is 106% less volatile than the S&P 500. Which has higher valuation and earnings, XTKG or KLDO? X3 has higher revenue and earnings than Kaleido Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioX3$11.61M2.19-$76.24MN/AN/AKaleido Biosciences$1.10M0.00-$95.48M-$2.24N/A Is XTKG or KLDO more profitable? Company Net Margins Return on Equity Return on Assets X3N/A N/A N/A Kaleido Biosciences N/A N/A N/A SummaryX3 beats Kaleido Biosciences on 4 of the 5 factors compared between the two stocks. Get Kaleido Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for KLDO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KLDO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KLDO vs. The Competition Export to ExcelMetricKaleido BiosciencesBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$426K$137.45M$5.51B$9.72BDividend YieldN/A3.74%4.60%4.12%P/E Ratio0.003.7830.0124.75Price / SalesN/A4,424.80450.7297.72Price / CashN/A13.1936.7758.47Price / BookN/A39.278.185.59Net Income-$95.48M-$90.99M$3.26B$265.99M Kaleido Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KLDOKaleido BiosciencesN/AN/AN/AN/A$426K$1.10M0.0080Gap UpXTKGX3N/A$1.82+4.0%N/A-76.8%$24.97M$11.61M0.00200Gap DownSEGGLottery.comN/A$0.93-6.7%N/A-14.2%$24.92M$1.07M-0.1050Gap DownSOGPLIZHI1.8299 of 5 stars$5.04-4.4%N/A+160.9%$24.90M$278.36M0.00750Gap DownMTCMMTecN/A$0.97+2.5%N/A-59.2%$24.32M$1.87M0.0060MTBLYMoatableN/A$1.36+4.0%N/A+115.4%$24.24M$52.07M-13.60410Gap UpSTIXSemantixN/AN/AN/AN/A$23.73M$264.23M0.004STRMStreamline Health SolutionsN/A$5.31+0.2%N/A-24.3%$23.15M$17.90M-2.33130AIXIXIAO-IN/A$1.80-5.8%N/AN/A$22.43M$70.31M0.00281HCTIHealthcare Triangle0.5886 of 5 stars$0.05-12.3%N/A-97.1%$20.75M$11.70M-0.0680News CoverageAnalyst DowngradeHigh Trading VolumeHKITHitek GlobalN/A$1.40+0.9%N/A+26.0%$20.15M$2.90M0.0075Positive News Related Companies and Tools Related Companies X3 Competitors Lottery.com Competitors LIZHI Competitors MMTec Competitors Moatable Competitors Semantix Competitors Streamline Health Solutions Competitors XIAO-I Competitors Healthcare Triangle Competitors Hitek Global Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KLDO) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kaleido Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kaleido Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
